Verve Therapeutics, Inc. (NASDAQ:VERV) Receives Average Rating of “Buy” from Analysts
Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) has been assigned a consensus rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have issued a report on the stock in […]
Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) has been assigned a consensus rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have issued a report on the stock in […]
